Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Net income margin (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndNet income margin (%) YoY (%)
Dec 31, 202443.7+28.80%
Dec 31, 202334+10.90%
Dec 31, 202230.6-66.29%
Dec 31, 202190.8+88.32%
Dec 31, 202048.2-230.88%
Dec 31, 2019-36.9-30.32%
Dec 31, 2018-52.9-365.96%
Dec 31, 201719.9-128.32%
Dec 31, 2016-70.2+194.29%
Dec 31, 2015-23.9-73.71%
Dec 31, 2014-90.8-40.42%
Dec 31, 2013-152.3+20.40%
Dec 31, 2012-126.5+258.95%
Dec 31, 2011-35.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat